Copper Complex Compositions for ALS Copper Imbalance Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases like ALS are limited, with only two FDA-approved agents that slow progression but do not cure the disease, and there is a need for improved therapeutic agents, especially targeting copper deficiency-related disorders.
Innovation Solution
Development of copper complexes, such as compounds of Formula (I) to (V), which are administered to treat or prevent neurodegenerative diseases by targeting copper metabolism imbalances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing FDA-approved agents (riluzole and edaravone) are used to treat ALS, then disease progression is slowed and life is extended by a few months, but the disease cannot be treated or cured
Solution Approach 1:
The patent changes the chemical parameter by introducing copper complexes with specific ligand structures (Formulas I-V) to achieve a fundamental therapeutic mechanism change. The copper complexes target copper metabolism imbalances and oxidative stress pathways differently than existing agents, aiming to transition from symptomatic management to potential disease modification or cure while maintaining life extension benefits
2Reliability
If copper complexes are developed to target copper metabolism imbalances, then therapeutic potential for curing neurodegenerative diseases is achieved, but the complexity of the therapeutic agent increases
Solution Approach 1:
The patent employs composite material design by combining copper ions with specifically designed organic ligands (pyridine, imidazole, triazole derivatives) to create copper complexes with optimized properties. This composite approach allows tuning of solubility, stability, and bioavailability while maintaining the therapeutic copper delivery function, thus managing complexity through systematic molecular design
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the ligand molecules (as defined in Formulas I-V with various R groups). This localized modification optimizes specific properties such as copper binding affinity, cellular uptake, and metabolic stability without redesigning the entire molecular structure, thereby managing complexity through targeted improvements
Data Source
AI summary
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).